97760-99-1 Usage
Uses
Used in Pharmaceutical Synthesis:
4-Cyano-3-(trifluoromethyl)acetanilide is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with enhanced properties. The presence of the cyano and trifluoromethyl groups allows for the creation of a diverse range of medicinal compounds with potential therapeutic applications.
Used in Agrochemical Production:
In the agrochemical industry, 4-Cyano-3-(trifluoromethyl)acetanilide serves as an intermediate in the production of various agrochemicals, including pesticides and herbicides. Its unique structural features enable the design of effective compounds for agricultural use, aiming to improve crop protection and yield.
Used in Dye and Pigment Manufacturing:
4-Cyano-3-(trifluoromethyl)acetanilide is utilized as an intermediate in the manufacturing of dyes and pigments, where its structural components contribute to the color and stability of the final products. This application is crucial in industries such as textiles, plastics, and printing inks.
Used in Fine Chemicals Industry:
4-Cyano-3-(trifluoromethyl)acetanilide is also employed in the production of other fine chemicals, where its reactivity and structural attributes are leveraged to create specialty chemicals for various applications, including but not limited to research, analytical chemistry, and the development of advanced materials.
Used in Medicinal Chemistry Research:
4-Cyano-3-(trifluoromethyl)acetanilide holds significant value in medicinal chemistry research, where it is used to explore the synthesis of novel compounds with potential biological activities. Its unique structural elements facilitate the investigation of structure-activity relationships and the discovery of new therapeutic agents.
Used in Industrial Production:
In industrial production, 4-Cyano-3-(trifluoromethyl)acetanilide is applied as a versatile intermediate for the synthesis of a wide array of chemical products. Its presence in the manufacturing process is essential for the creation of innovative and high-quality industrial chemicals that meet various market demands.
Check Digit Verification of cas no
The CAS Registry Mumber 97760-99-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,7,6 and 0 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 97760-99:
(7*9)+(6*7)+(5*7)+(4*6)+(3*0)+(2*9)+(1*9)=191
191 % 10 = 1
So 97760-99-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H7F3N2O/c1-6(16)15-8-3-2-7(5-14)9(4-8)10(11,12)13/h2-4H,1H3,(H,15,16)
97760-99-1Relevant academic research and scientific papers
Bacillus subtilis epoxide hydrolase-catalyzed preparation of enantiopure 2-methylpropane-1,2,3-triol monobenzyl ether and its application to expeditious synthesis of (R)-bicalutamide
Fujino, Aya,Asano, Masayoshi,Yamaguchi, Hitomi,Shirasaka, Naoki,Sakoda, Akiko,Ikunaka, Masaya,Obata, Rika,Nishiyama, Shigeru,Sugai, Takeshi
, p. 979 - 983 (2008/02/04)
Expeditious synthesis of (R)-bicalutamide (1), a synthetic antiandrogen, from enantiopure 2-methylpropane-1,2,3-triol monobenzyl ether (4) was achieved. An engineered Bacillus subtilis epoxide hydrolase worked enantioselectively on the racemic epoxide (7) to provide the above starting material in highly enantiomerically enriched state.
Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgen receptor modulators
Hamann, Lawrence G.,Manfredi, Mark C.,Sun, Chongqing,Krystek Jr., Stanley R.,Huang, Yanting,Bi, Yingzhi,Augeri, David J.,Wang, Tammy,Zou, Yan,Betebenner, David. A.,Fura, Aberra,Seethala, Ramakrishna,Golla, Rajasree,Kuhns, Joyce E.,Lupisella, John A.,Darienzo, Celia J.,Custer, Laura L.,Price, Jennifer L.,Johnson, James M.,Biller, Scott A.,Zahler, Robert,Ostrowski, Jacek
, p. 1860 - 1864 (2008/02/04)
Pharmacokinetic studies in cynomolgus monkeys with a novel prototype selective androgen receptor modulator revealed trace amounts of an aniline fragment released through hydrolytic metabolism. This aniline fragment was determined to be mutagenic in an Ames assay. Subsequent concurrent optimization for target activity and avoidance of mutagenicity led to the identification of a pharmacologically superior clinical candidate without mutagenic potential.
